Streetbeat News

Analyst Ratings

SWTX

JP Morgan analyst Anupam Rama has maintained an Overweight rating on SpringWorks Therapeutics and raised the price target from $64 to $68.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:02 pm

AMRC

In the past three months, four analysts have provided ratings on Ameresco (NYSE:AMRC), with a mix of somewhat bullish and indifferent perspectives. The average 12-month price target has increased by 3.79% to $34.25. Ameresco has shown strong revenue growth but faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 9:01 pm

RRR

Analysts have provided a range of ratings for Red Rock Resorts (NASDAQ:RRR) over the past three months, with a recent increase in the average 12-month price target to $63.2. The company's financial performance is strong, with impressive revenue growth and profitability metrics, though it has a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 9:01 pm

BANC

Analysts have provided mixed ratings for Banc of California (NYSE:BANC) over the past three months, with most maintaining an 'Indifferent' stance. The average 12-month price target has decreased from $15.00 to $14.5. Despite strong revenue growth and net margins, the company faces challenges with low ROE, ROA, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 9:00 pm

EPAM

In the past three months, 8 analysts have provided ratings for EPAM Systems (NYSE:EPAM), with a mix of bullish to bearish perspectives. The average 12-month price target is $223.25, a 2.16% decrease from the previous target. Analysts have adjusted their ratings and price targets based on market conditions and company performance. EPAM Systems, a global IT services firm, faces revenue challenges but maintains strong profitability and effective cost control.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 9:00 pm

PRAX

Analysts have varied ratings for Praxis Precision Medicine (NASDAQ:PRAX), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 3.45% to $144.64. Despite challenges like a 54.29% revenue decline, PRAX shows strong ROE and low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 9:00 pm

SHLS

Shoals Technologies Gr (NASDAQ:SHLS) has received mixed analyst ratings over the past three months, with a notable decrease in the average 12-month price target by 26.04%. Analysts have adjusted their ratings and price targets, reflecting a negative shift in sentiment. Despite challenges in revenue growth, Shoals Technologies Gr maintains strong financial metrics such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 9:00 pm

SG

TD Cowen analyst Andrew Charles upgraded Sweetgreen Inc (NYSE:SG) from Hold to Buy, raising the price target from $31 to $43. The upgrade is based on Sweetgreen's technological innovations, particularly the Infinite Kitchen's robotic equipment, which is expected to significantly boost margins and EBITDA by 2030. The analyst also highlighted strong same-store sales and various sales drivers, including new product launches and marketing efforts.

Portfolio Pulse from Anusuya Lahiri

September 04, 2024 | 8:58 pm

ELF

Deep-pocketed investors are showing a bullish sentiment towards e.l.f. Beauty (NYSE:ELF) as indicated by significant options activity. The options market reveals a price target range of $90 to $310, with 70% of the activity being bullish. Analysts have set an average price target of $230.6, with some revising their ratings and targets. The stock is currently down 2.08% at $137.32, with RSI indicators suggesting it may be oversold.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 8:45 pm

SPOT

Investors are showing significant interest in Spotify Technology's options market, with a notable bullish sentiment. The options activity suggests a potential price range of $210 to $360 for SPOT, with a current trading price of $329.25. Expert opinions remain positive, with a target price of $460.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 8:45 pm